H<sub>2</sub>S和sST2与射血分数降低的心力衰竭的相关性研究

何智余; 武锋超; 马兰虎; 张涛; 朱文彤; 张益铭; 蓝庆肃; 姚亚丽

doi:10.13201/j.issn.1001-1439.2020.10.011

H₂S和sST2与射血分数降低的心力衰竭的相关性研究

- 1. 兰州大学第一医院心脏中心(兰州, 730000);
- 2. 兰州大学第一临床医学院;
- 3. 金昌市中西医结合医院心内科;
- 4. 兰州大学第二医院心内科
基金项目:
甘肃省卫生行业科研计划项目(No:GSWSDY-2015-44)

甘肃省卫生行业科研计划项目(No:GSWSDY-2015-45)

详细信息

通讯作者: 姚亚丽,E-mail:yaoyalifs@163.com

中图分类号: R541.6

收稿日期: 2020-06-07

修回日期: 2020-08-11

Correlation between H₂S, soluble ST2 and heart failure with reduced ejection fraction

- 1. Department of Cardiology, the First Hospital of Lanzhou University, Lanzhou, 730000, China;
- 2. The First Clinical Medical College, Lanzhou University;
- 3. Department of Cardiology, Jinchang Integrated Chinese and Western Medicine Hospital;
- 4. Department of Cardiology, the Second Hospital of Lanzhou University

More Information

Corresponding author: YAO Yali, E-mail: yaoyalifs@163.com

Received Date: 07 June 2020

Revised Date: 11 August 2020

摘要

摘要: 目的:测定射血分数降低的心力衰竭(HFrEF)患者及正常对照者的血浆硫化氢(H₂S)和可溶性ST2(sST2)的浓度,以明确血浆H₂S及sST2对HFrEF的诊断价值。方法:分别收集117例HFrEF患者(心衰组)及52例健康体检者(对照组)。收集相关基线资料,采用ELISA法检测血浆H₂S与sST2浓度,采用心脏超声测定左室舒张末期容积(LVEDV)、左室收缩期容积(LVESV)、左室短轴缩短率(LVFS)、左室射血分数(LVEF)。相关性分析采用Spearman检验,受试者工作特征曲线(ROC)用以评价H₂S及sST2对HFrEF的诊断价值。结果:心衰组与对照组血浆H₂S浓度无明显统计学差异。与对照组相比,心衰组sST2与NT-proBNP水平均显著增高(均P<0.05),且NYHA分级越高,sST2与NT-proBNP水平越高。Spearson相关性分析显示,sST2与NYHA、LVEDV、LVESV、NT-proBNP呈正相关(r=0.620、0.388、0.482、0.506,均P<0.05),与LVEF、LVFS呈负相关(r=-0.568、-0.424,均P<0.05)。ROC曲线显示,sST2诊断HFrEF的AUC为0.857(95%CI:0.789~0.926),敏感度和特异度分别为76.1%和86.5%,截点值为31.53 ng/ml。sST2与NT-proBNP联合诊断HFrEF的AUC达0.963(95%CI:0.935~0.991),敏感度和特异度分别为93.2%和94.2%。结论:HFrEF患者血浆H₂S水平无明显差异,sST2水平随着NYHA分级的升高而升高,且与心功能有关。sST2与NT-proBNP联合检测可有效提高HFrEF的诊断效率。
- 射血分数降低的心力衰竭 /
- 硫化氢 /
- 可溶性ST2
Abstract: Objective: To determine the plasma hydrogen sulfide(H₂S) and soluble ST2(sST2) concentrations in patients with a reduced ejection fraction of heart failure(HFrEF) and normal controls, to determine the diagnostic value of H₂S and sST2 in HFrEF. Method: A total of 117 HFrEF patients(heart failure group) and 52 healthy subjects(control group) were collected. Relevant baseline data were collected, plasma H₂S and sST2 concentrations were detected by ELISA, and left ventricular end-diastolic volume(LVEDV), left ventricular end-systolic volume(LVESV), left ventricular short-axis shortening rate(LVFS), and left ventricular ejection fraction(LVEF) were measured by cardiac color ultrasound. Spearman test was used for correlation analysis, receiver operating characteristic curve(ROC) was used to evaluate the diagnostic value of H₂S and sST2 for HFrEF. Result: There was no significant difference in plasma H₂S concentration between heart failure and control group. Compared with the control group, the levels of sST2 and NT-proBNP in heart failure group increased significantly(both P<0.05), and the higher the NYHA classification, the higher the level of sST2 and NT-proBNP. Spearson analysis showed that sST2 was positively correlated with NYHA, LVEDV, LVESV and NT-proBNP(r=0.620, 0.388, 0.482, 0.506, all P<0.05), and negatively correlated with LVEF and LVFS(r=-0.568,-0.424, both P<0.05). ROC(AUC) in diagnosing HFrEF was 0.857(95%CI: 0.789-0.926), the sensitivity and specificity were 76.1% and 86.5%, respectively, the cut-off value was 31.53 ng/ml. The AUC of sST2 combined with NT-proBNP was 0.963(95%CI: 0.935-0.991), the sensitivity and specificity were 93.2% and 94.2%, respectively.Conclusion: There is no significant difference in plasma H₂S in HFrEF patients. The level of sST2 increases with the increase of NYHA grade and is related to cardiac function. The combination detection of sST2 and NT-proBNP can effectively improve the diagnostic efficiency of HFrEF.
- heart failure with reduced ejection fraction /
- hydrogen sulfide /
- soluble ST2

HTML全文

参考文献(26)

[1]	中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[2]	Ziaeian B,Fonarow GC.Epidemiology and aetiology of heart failure[J].Nat Rev Cardiol,2016,13(6):368-378.
[3]	Lee SR,Nilius B,Han J.Gaseous signaling molecules in cardiovascular function:from mechanisms to clinical translation[J].Rev Physiol Biochem Pharmacol,2018,174:81-156.
[4]	Polhemus DJ,Lefer DJ.Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease[J].Circ Res,2014,114(4):730-737.
[5]	Polhemus DJ,Calvert JW,Butler J,et al.The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure[J].Scientifica(Cairo),2014,2014:768607.
[6]	Tominaga S.A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1receptor[J].FEBS Lett,1989,258(2):301-304.
[7]	Pascual-Figal DA,Januzzi JL.The biology of ST2:the International ST2 Consensus Panel[J].Am J Cardiol,2015,115(7 Suppl):3B-7B.
[8]	Aimo A,Januzzi JL Jr,Bayes-Genis A,et al.Clinical and prognostic significance of sST2 in heart failure:JACC review topic of the week[J].J Am Coll Cardiol,2019,74(17):2193-2203.
[9]	Kang SC,Sohn EH,Lee SR.Hydrogen sulfide as a potential alternative for the treatment of myocardial fibrosis[J].Oxid Med Cell Longev,2020,2020:4105382.
[10]	Kondo K,Bhushan S,King AL,et al.H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase[J].Circulation,2013,127(10):1116-1127.
[11]	Liu YH,Lu M,Xie ZZ,et al.Hydrogen sulfide prevents heart failure development via inhibition of renin release from mast cells in isoproterenol-treated rats[J].Antioxid Redox Signal,2014,20(5):759-769.
[12]	Kovači ćD,Glavnik N,Marinšek M,et al.Total plasma sulfide in congestive heart failure[J].J Card Fail,2012,18(7):541-548.
[13]	Peter EA,Shen X,Shah SH,et al.Plasma free H2S levels are elevated in patients with cardiovascular disease[J].J Am Heart Assoc,2013,2(5):e000387.
[14]	Jin HF,Liang C,Liang JM,et al.[Effects of hydrogen sulfide on vascular inflammation in pulmonary hypertension induced by high pulmonary blood flow:experiment with rats][J].Zhonghua Yi Xue Za Zhi,2008,88(32):2235-2239.
[15]	Millar NL,O'Donnell C,McInnes IB,et al.Wounds that heal and wounds that don't-The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis[J].Semin Cell Dev Biol,2017,61:41-50.
[16]	Kotsiou OS,Gourgoulianis KI,Zarogiannis SG.IL-33/ST2 Axis in Organ Fibrosis[J].Front Immunol,2018,9:2432.
[17]	Matilla L,Ibarrola J,Arrieta V,et al.Soluble ST2promotes oxidative stress and inflammation in cardiac fibroblasts:an in vitro and in vivo study in aortic stenosis[J].Clin Sci(Lond),2019,133(14):1537-1548.
[18]	Tang WH,Wu Y,Grodin JL,et al.Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure[J].JACC Heart Fail,2016,4(1):68-77.
[19]	许卓帆,郑韶欣,叶贤区,等.慢性心力衰竭患者血清sST2、Galectin-3水平变化及临床意义[J].中国循证心血管医学杂志,2020,12(1):47-49,53.
[20]	袁伟,顾宇英,张代富.心力衰竭患者血清可溶性ST2水平的测定及其诊断价值[J].第二军医大学学报,2012,33(2):175-178.
[21]	Plawecki M,Morena M,Kuster N,et al.sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling:impact on risk prediction[J].Mediators Inflamm,2018,2018:3952526.
[22]	Mueller T,Jaffe AS.Soluble ST2--analytical considerations[J].Am J Cardiol,2015,115(7 Suppl):8B-21B.
[23]	Aimo A,Januzzi JL Jr,Vergaro G,et al.Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal proB-type natriuretic peptide and high-sensitivity troponin T[J].Eur J Heart Fail,2020.
[24]	Emdin M,Aimo A,Vergaro G,et al.sST2 predicts outcome in chronic heart failure beyond NT-proBNPand high-sensitivity troponin T[J].J Am Coll Cardiol,2018,72(19):2309-2320.
[25]	Song Y,Li F,Xu Y,et al.Prognostic value of sST2 in patients with heart failure with reduced,mid-range and preserved ejection fraction[J].Int J Cardiol,2020,304:95-100.
[26]	Zhang R,Zhang Y,Zhang J,et al.The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure[J].PLoS One,2014,9 (10):e110976.